Atrial fibrillation (AF) is a common cardiac arrhythmia. Dabigatran etixalate (DE) is one of the
new oral anticoagulant drugs being used in nonvalvular AF (NVAF). There is no adequate …

Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …

Objective To analyze the rationality of dabigatran application in the patients with nonvalvular
atrial fibrillation (NVAF), as well as the safety and adherence, so as to better guide clinical …

Abstract 1169 INTRODUCTION: New oral anticoagulants (NOACs) have been recently
approved by the European Medicine Agency (EMA) and the Food and Drug Administration …

We read with interest the recent prospective observational study by Chan et al.[1] The
authors aimed to investigate the interpatient and intrapatient variabilities in dabigatran …

Background Issues with laboratory measurement of dabigatran include: 1. Do coagulation
assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with …

Abstract Aims The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY)
trial allowed patients who completed the trial receiving their assigned dabigatran 150 mg …

Background: Dabigatran is prescribed to increasing numbers of patients with atrial fibrillation
(AF). Although routine monitoring is not considered to be useful, measuring drug …

We aimed to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model from
healthy Chinese subjects and real-world nonvalvular atrial fibrillation (NVAF) patients. We …

Purpose Dabigatran concentrations monitoring are gaining importance of special situations,
but limited data is available for the expected peak and trough levels. The Hemoclot …